Bio-Rad Q4 Revenue Rises 3.9% to $667.5M, Annual Free Cash Flow $375M
Bio-Rad Laboratories posted Q4 revenue of $667.5M, up 3.9%, with net income of $67.7M ($2.51/share). Full-year revenue rose 0.7% to $2.58B while net income fell to $270.5M ($9.92/share); the company generated $375M of free cash flow and forecasts 0.5–1.5% revenue growth with a 12–12.5% non-GAAP margin next year.
1. Q4 Financial Performance
In the fourth quarter, Bio-Rad reported revenue of $667.5 million, a 3.9% increase driven by growth in its Clinical Diagnostics segment. Net income decreased to $67.7 million, or $2.51 per diluted share, reflecting margin pressures despite higher top-line sales.
2. Full-Year Results and Cash Flow
For the fiscal year, revenue rose 0.7% to $2.58 billion while net income fell to $270.5 million, or $9.92 per share. The company generated $532 million in cash from operations and delivered $375 million of free cash flow, underpinned by cost controls.
3. Acquisition Integration and Outlook
Bio-Rad successfully integrated Stilla Technologies to expand its droplet digital PCR leadership. Management expects revenue growth of 0.5–1.5% and a non-GAAP operating margin of 12–12.5% in the upcoming year, indicating modest expansion.